Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at EHRA 2021, an online scientific congress of the European Society of Cardiology (ESC).1
Study author Professor Susanne Pedersen of Odense University Hospital, Denmark said: “Most patients adapt well to living with an ICD. For others it completely changes their life, with worries about shocks from the device, body image, and livelihood as some need to change their job.”
Previous studies have shown that anxious or depressed ICD patients have poorer quality of life and increased risks of arrhythmias and death.2,3,4 This study examined how many patients develop anxiety or depression after ICD implantation, as screening tends to be a one-time event.
The study used data from DEFIB-WOMEN, a national, multicentre, prospective, observational study of patients with a first-time ICD.5,6 Patients who received a first-time ICD were recruited consecutively between June 2010 to April 2013 at five hospitals in Denmark and followed up for 24 months.
The study included 1,040 patients who completed questionnaires on anxiety, depression, and physical quality of life at baseline, and 3, 6, 12, and 24 months. Information on demographic and clinical data was obtained from the Danish Pacemaker and ICD Register.
With respect to new onset anxiety, the cumulative incidence over the 24-month follow-up period was 14.5%. With respect to new onset depression, the cumulative incidence over the 24-month follow-up period was 11.3%.
Greater age was associated with a reduced risk of new onset anxiety, with a hazard ratio (HR) of 0.54, while being married, Type D personality, and lower self-reported physical functioning were associated with an increased risk, with HRs of 1.66, 2.50, and 1.48, respectively.
Regarding new onset depression, higher age and higher self-reported physical functioning were associated with reduced risk, with HRs of 0.57 and 0.46, respectively. Smoking, type D personality, and lower self-reported physical functioning were associated with an increased risk, with HRs of 2.13, 2.53, and 1.64, respectively.
“Our results suggest that more regular screening for depression and anxiety could identify patients who might benefit from additional support,” said Professor Pedersen. “Taken together, our findings indicate that younger patients, those with poor physical function, and those with type D personality are more likely to become anxious or depressed. People with type D personality tend to worry while not sharing negative emotions with others, which may compromise their mental health.”
Professor Pedersen noted that ICD implantation is often a day procedure. While some patients look forward to going home, others become anxious and feel it is too soon as they have had no time to adjust. She said: “One way to remedy this could be digital support, using an app or platform to provide information and reassurance, enabling patients to talk to a health professional if needed, and referring those with high anxiety or depression scores to a psychologist for an online treatment programme. We are piloting this approach, and in my experience, it is a minority of patients who need it, but for those who do, it can mean a world of difference.”
Authors: ESC Press Office
Tel: +33 (0)4 89 87 20 85
Mobile: +33 (0)7 8531 2036
Email: [email protected]
Follow us on Twitter @ESCardioNews
Notes to editor
Funding: The DEFIB-WOMEN study is supported with a grant (09-10-R75-A2713-22565) from the Danish Heart Foundation.
References and notes
1Abstract title: New onset depression and anxiety in patients with an implantable cardioverter defibrillator during 24 months of follow-up.
2Habibovi? M, Pedersen SS, van den Broek KC, et al. Anxiety and risk of ventricular arrhythmias or mortality in patients with an implantable cardioverter defibrillator. Psychosom Med. 2013;75:36-41.
3Andersen CM, Theuns DAMJ, Johansen JB, et al. Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7 years’ follow-up of the MIDAS cohort. Gen Hosp Psychiatry. 2020;66:154-160.
4Mastenbroek MH, Versteeg H, Jordaens L, et al. Ventricular tachyarrhythmias and mortality in patients with an implantable cardioverter defibrillator: impact of depression in the MIDAS cohort. Psychosom Med. 2014;76:58-65.
5DEFIB-WOMEN: utilisation of implantable cardioverter DEFIBrillator therapy in the treatment of heart disease: Clinical and psychological outcomes in WOMEN.
6Pedersen SS, Nielsen JC, Riahi S, et al. Study design and cohort description of DEFIB-WOMEN: A national Danish study in patients with an ICD. Pacing Clin Electrophysiol. 2016;39:1261-1268.
About the European Heart Rhythm Association
The European Heart Rhythm Association (EHRA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve patients’ quality of life and reduce sudden cardiac death by limiting the impact of heart rhythm disturbances.
About the EHRA Congress #EHRA2021
EHRA 2021 is the online annual congress of the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
Information for journalists about registration for EHRA 2021
EHRA 2021 takes place 23 to 25 April online.
* Free registration applies only to accredited press.
* Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related or referring to a previous ESC event). Read the ESC media and embargo policy.
* The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
* The ESC Press Office decision is final regarding all press registration requests.
World News || Latest News || U.S. News